Why Illumina (ILMN) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research • Dec 12, 2025

Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme's Clinical Trial That Could Save U.S. Healthcare $200 Billion Annually

Partnership unites Illumina's leading sequencing technology with cutting-edge clinical genomics analyses and AI to advance precision medicine for early detection and prevention. SAN DIEGO and MENLO PARK, Calif.

PRNewsWire • Dec 11, 2025

Bet on These 3 Stocks With Upgraded Broker Ratings Amid Uncertainties

Illumina, Commercial Metals and Newmont have all seen broker upgrades, signaling bullish momentum amid market uncertainties.

Zacks Investment Research • Dec 8, 2025

New Strong Buy Stocks for December 4th

ZTO, BG, FHI, SPNT and ILMN have been added to the Zacks Rank #1 (Strong Buy) List on Dec. 4, 2025.

Zacks Investment Research • Dec 4, 2025

Illumina (ILMN) Moves to Strong Buy: Rationale Behind the Upgrade

Illumina (ILMN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Zacks Investment Research • Dec 3, 2025

Illumina, Inc. (ILMN) Presents at 7th Annual Wolfe Research Healthcare Conference Transcript

Illumina, Inc. ( ILMN ) 7th Annual Wolfe Research Healthcare Conference November 19, 2025 9:20 AM EST Company Participants Jacob Thaysen - CEO & Director Conference Call Participants Douglas Schenkel - Wolfe Research, LLC Presentation Douglas Schenkel Wolfe Research, LLC Okay. Good morning, everybody.

Seeking Alpha • Nov 19, 2025

Illumina whole-genome sequencing provides greater insight into genetic signals behind common diseases--according to Nature study

Study shows that rare variants captured by Illumina WGS with DRAGEN™ variant calling explain most of the "missing heritability" in complex human diseases and traits, including those related to blood pressure and cholesterol Results demonstrate the advantages of WGS over WES and genotyping arrays for assessing genetic risk and identifying drug target candidates. SAN DIEGO , Nov. 12, 2025 /PRNewswire/ -- A study published today in Nature , authored by Illumina, Inc. (NASDAQ: ILMN) scientists and by collaborators from The University of Queensland demonstrates the importance of whole-genome sequencing (WGS) to more fully capture the genetics underlying complex human traits and diseases.

PRNewsWire • Nov 12, 2025

Illumina To Webcast Upcoming Investor Conference

SAN DIEGO , Nov. 11, 2025 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) today announced that its executives will be speaking at the following investor conference: Wolfe Research Healthcare Conference 2025 on November 19, 2025 Fireside chat at 6:20am Pacific Time (9:20am Eastern Time) The webcast can be accessed through the Investor Info section of Illumina's website at investor.illumina.com. A replay will be posted on Illumina's website after the event and will be available for at least 30 days following.

PRNewsWire • Nov 11, 2025

ALKS or ILMN: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Alkermes (ALKS) and Illumina (ILMN). But which of these two stocks presents investors with the better value opportunity right now?

Zacks Investment Research • Nov 11, 2025

Final Trades: Morgan Stanley, Cisco Systems, Illumina and FTAI Aviation

The Investment Committee give you their top stocks to watch for the second half.

CNBC Television • Nov 10, 2025